These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19143674)

  • 21. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.
    Pincus T; Yazici Y; van Vollenhoven R
    J Rheumatol; 2006 Dec; 33(12):2372-5. PubMed ID: 17143975
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of progestogens in pregnant and infertile patients.
    Ozlü T; Güngör AC; Dönmez ME; Duran B
    Arch Gynecol Obstet; 2012 Aug; 286(2):495-503. PubMed ID: 22543698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 24. [Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease].
    Michetti P
    Rev Med Suisse; 2008 Jan; 4(141):187-8. PubMed ID: 18335883
    [No Abstract]   [Full Text] [Related]  

  • 25. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2007 Apr; 46(4):695-8. PubMed ID: 17158212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-TNF-alpha therapy for heart failure: etanercept, infliximab].
    Matsumori A
    Nihon Rinsho; 2007 May; 65 Suppl 5():176-81. PubMed ID: 17569314
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical trials. Gene transfer an unlikely contributor to patient's death.
    Kaiser J
    Science; 2007 Dec; 318(5856):1535. PubMed ID: 18063761
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies.
    Paccou J; Solau-Gervais E; Houvenagel E; Salleron J; Luraschi H; Philippe P; Duquesnoy B; Flipo RM
    Rheumatology (Oxford); 2011 Apr; 50(4):714-20. PubMed ID: 21131271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Glycocorticoid hormones and sterility].
    Dimitrov DIa; Andreev Zh
    Akush Ginekol (Sofiia); 1970; 9(5):387-98. PubMed ID: 5526637
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical study on the usefulness of sairei-to for the infertile patients with positive autoantibody].
    Tanaka E; Takahashi T; Ohno T; Oda T
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Apr; 47(4):421-4. PubMed ID: 7730698
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-tumour necrosis factor-alpha therapy in heart failure: future directions.
    Balakumar P; Singh M
    Basic Clin Pharmacol Toxicol; 2006 Dec; 99(6):391-7. PubMed ID: 17169118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.
    Henderson C; Davis JC
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):211-8. PubMed ID: 16932687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
    Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
    Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 36. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Rosner I; Haddad A; Boulman N; Feld J; Avshovich N; Slobodin G; Rozenbaum M
    Rheumatology (Oxford); 2007 Sep; 46(9):1508; author reply 1508-9. PubMed ID: 17684027
    [No Abstract]   [Full Text] [Related]  

  • 37. [Allogeneic leukocyte immunization combined with IVF-ET for treatment of infertility induced by recurrent spontaneous abortion].
    Kong LH; Liu Z; Li H; Chen SM; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1300-1. PubMed ID: 18676284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphea, an unusual side effect of anti-TNF-alpha treatment.
    Mattozzi C; Richetta AG; Cantisani C; Giancristoforo S; D'Epiro S; Gonzalez Serva A; Viola F; Cucchiara S; Calvieri S
    Eur J Dermatol; 2010; 20(3):400-1. PubMed ID: 20299314
    [No Abstract]   [Full Text] [Related]  

  • 39. Intracellular cytokine expression of peripheral blood natural killer cell subsets in women with recurrent spontaneous abortions and implantation failures.
    Fukui A; Kwak-Kim J; Ntrivalas E; Gilman-Sachs A; Lee SK; Beaman K
    Fertil Steril; 2008 Jan; 89(1):157-65. PubMed ID: 17482605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.